In this photo illustration, the Amicus Therapeutics logo is displayed on the screen of a tablet. <\/p>\n
Sheldon Cooper | Lightrocket | Getty Images<\/p>\n
BioMarin Pharmaceutical<\/a> said on \u2060Friday it would acquire Amicus \u200dTherapeutics<\/a> \u200dfor about $4.8 \u200dbillion, expanding its presence in rare metabolic diseases.<\/p>\n The \u200ddrugmaker will \u200dpay $14.50 per share for Amicus, a premium of 33.1% to the stock’s last close. Shares of Amicus surged 30%, \u200cwhile \u200cBioMarin rose nearly 5% in \u200bpremarket trading.<\/p>\n The deal strengthens BioMarin’s portfolio with Amicus’ approved genetic disorder treatments, including Galafold, an oral drug for Fabry disease, which is \u2060caused by a faulty gene that leads to a buildup of fatty substances in cells.<\/p>\n Amicus also markets a combination therapy, Pombiliti and Opfolda, for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body’s cells.<\/p>\n Amicus also has U.S. rights to DMX-200, a potential treatment for a type of kidney disease known as focal segmental glomerulosclerosis.<\/p>\n BioMarin intends to finance the deal through a combination of cash on hand \u200dand about $3.7 billion of non-convertible debt financing.<\/p>\n The company’s total \u200ccash and investments at the end \u2060of September 30 were about $2 billion.<\/p>\n The acquisition, which is expected to close in the second quarter \u200dof 2026, will add revenue immediately after the transaction closes, BioMarin said.<\/p>\n The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning \u2060in 2027, the company said. <\/p>\n","protected":false},"excerpt":{"rendered":"In this photo illustration, the Amicus Therapeutics logo is displayed on the screen of a tablet. Sheldon Cooper…\n","protected":false},"author":2,"featured_media":358341,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[177374,177373,2602,28,122,2601],"class_list":["post-358340","post","type-post","status-publish","format-standard","has-post-thumbnail","category-business","tag-amicus-therapeutics-inc","tag-biomarin-pharmaceutical-inc","tag-biotech-and-pharmaceuticals","tag-business","tag-business-news","tag-health-care-industry"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/358340","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=358340"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/358340\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/358341"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=358340"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=358340"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=358340"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}